Skip to main content
. Author manuscript; available in PMC: 2014 Sep 10.
Published in final edited form as: Metabolomics (Los Angel). 2012 Mar 21;2(3):1000108. doi: 10.4172/2153-0769.1000108

Table 1.

Frequently deregulated miRNAs in lung cancer

miRNA Expression
Confirmed targets Associated with Reference
NSCLC SCLC
Tumors Lines Tumors Lines Diagnosis Survival1
let-7 Dn Dn UC HMGA2, RAS, MYC, E2Fs, CDKs SCC NSCLC [24, 25, 54, 65, 77, 78, 80, 81, 105]
miR-7 Up Up ETS2, EGFR, Raf1 [24, 54]
miR-9 Dn/Up Up TGFBI, TRIM2, SIRT1, BTBD3 SCLC [24, 25, 54, 106]
miR-15 Up NC Up Dn/Up Bcl-2, CCND1, CCNE NSCLC [10, 54, 77–79]
miR-16 Dn NC Dn/Up Bcl-2, CCND1, CCNE NSCLC [10, 24, 54, 65, 79]
miR-17-3p,5p Up Up Up p21, E2F, Bim, CCND1, PTEN, Rb NSCLC [25, 40, 54, 77, 78, 107]
miR-17-92 cluster Up Up Up Up p21, E2F, CCND1, PTEN, Rb, HIF-1α SCLC SCLC [40, 54]
miR-20 Up Up p21, E2F, Bim, Cyclin D1, PTEN, Rb NSCLC [40, 54, 77, 78]
miR-21 Up Up UC Dn Apaf-1, PTEN, PDCD4, Faslg, Spry1-2, Btg2 NSCLC; ADC NSCLC [10, 23–25, 43, 44, 54, 64, 65, 77–79, 95, 107, 108]
miR-22 UC Dn PTEN, ESR1, TIAM1 [10, 109, 110]
miR-23a,b Up NC Dn Has2, LaminB1, Brn-3b NSCLC [10, 54, 79]
miR-24 Up NC Dn E2F2, Myc, Net1A NSCLC [10, 25, 79]
miR-25 Up Up Up Bim, TRAIL NSCLC NSCLC [54, 60, 78, 111]
miR-27b Dn UC UC ST14, PPARα NSCLC [25, 54, 79]
miR-29a,b,c Dn NC Dn Dn DNMT3 (A&B) [10, 23, 25, 54]
miR-30 Dn Dn p53, B-Myb, CTGF [22–25, 54, 65]
miR-30c, d Dn Up Up Serpine1 NSCLC [10, 65, 79, 82, 112]
miR-31 Up Dn Dn LATS2, PPP2R2A ADC [10, 23, 46, 64, 65]
miR-32 Dn Dn Bim [25, 54]
miR-33 Dn Dn ABCA1, p53 [25, 54, 113, 114]
miR-34a Dn/Up Dn DLL1, CDK4, Myc, CCND1 NSCLC [23, 54, 78, 115, 116]
miR-92 UC Up Bim [10, 54, 117]
miR-93 UC Up p21, FUS1 SCLC [10, 54, 111, 118]
miR-95 Dn Up Up SNX1 SCLC [25, 54, 119]
miR-96 Up Up Up Up GPC3, FOXO1 NSCLC [10, 54, 120]
miR-98 UC Up Up FUS1 SCLC [10, 54, 93, 118]
miR-99 Dn Dn SMARCA5, SMARCD1, mTOR [10, 23, 65, 121]
miR-100 Dn Dn ATM, PLK1, MTOR, RPTOR, IGF1R, Gli1 SCC [23, 54, 77, 78]
miR-101 Dn Up Up Mcl-1 [10, 22–25, 47–49]
miR-106a Up Up Up E2F1 ADC OS-NSCLC [10, 54, 77, 78, 111]
miR-106b Up Up p21, E2F, Bim, Cyclin D1, PTEN, Rb [10, 54, 77, 78, 111]
miR-125 Dn Dn Dn Smo, invasion and migration factors NSCLC [23, 25, 54, 65, 77, 122]
miR-126 Dn Dn Dn Spred-1 SCC, ADC SCC [22–25, 64, 65, 77, 78]
miR-126* Dn ERBB2IP NSCLC [23–25, 95]
miR-128 Dn Up EGFR SCLC EGFR-TKi2 [45, 54]
miR-130a Dn Dn MET NSCLC [23, 24, 54, 65, 79]
miR-130b Up Up Up CSF-1, TP53INP1, RUNX3 SCC [54, 64, 65]
miR-133b Dn Dn Mcl-1, BCLw [24, 54]
miR-139 Dn ROCK2, FOXO1, CXCR4 SCC [24, 64, 65, 123–125]
miR-140 Dn Sp1, BMP2 ADC [25, 64]
miR-142-3p,5p Up Dn/Up ADAM9, GRα, PKA [10, 54]
miR-143 Dn Dn ERK5, KRAS, Bcl-2, DNMT3A, ELK1 ADC [23–25, 54, 64]
miR-145 Dn Dn c-MYC, CDK4, eIF4E4 NSCLC; ADC [23, 25, 54, 64, 95]
miR-146b Up Dn MMP16, TRAF6, IRAK1, ADC SCC [25, 54, 77, 78, 107]
miR-149 Up Up Up E-cadherin SCC [10, 55, 65]
miR-150 Up/Dn Dn Dn MUC4, P2RX7 ADC [25, 54, 64]
miR-155 Up Dn TAB2, FADD, RIP-1, IKKε, ET -1 ADC NSCLC [25, 54, 61, 77, 78, 107]
miR-181a,b Dn Dn Dn Mcl-1, Bcl-2 [23, 54, 65]
miR-181c Dn NC Up TGFBI, TRIM2, SIRT1, BTBD3 [10, 65, 106]
miR-182 Up Up Up FOXO1 NSCLC, ADC NSCLC [24, 54, 61, 64, 65, 77, 78, 80, 95, 120]
miR-183 Up Up Up FOXO3, FOXO1, EGR1, PTEN NSCLC NSCLC [24, 54, 65, 77, 95, 120]
miR-185 Dn Dn Dn c-Myc, DNMT1, SMG6, CDK6, AKT1 [54, 126]
miR-191 Up Dn CDK6, TIMP3, NDST1 ADC SCC [25, 54, 77, 78, 107]
miR-192 Up ERCC3, ERCC4, Rb1 [25, 107]
miR-195 Dn NC Dn/Up CCNE, BCLw [10, 24, 54, 65]
miR-197 Up Up Up FUS1 [10, 25, 61]
miR-199 Dn Dn Dn Dn HES, ET-1, HIF-1α [10, 21, 25, 54]
miR-200a,b Dn/Up Up Up C-ets-1, Zeb1, ECM proteins, p38α ADC NSCLC [54, 64, 79, 127]
miR-200c Up Dn Up Up C-ets-1, Zeb1, ECM proteins SCC NSCLC [54, 65, 77, 128]
miR-203 Up . DeltaNp63, Smo NSCLC, ADC [25, 77, 107]
miR-205 Up Dn Dn E2F1, Zeb1, Sip1 SCC; ADC [10, 25, 65, 74, 75, 78, 93, 107]
miR-210 Up Up Up HOXA1, FGFRL1, HOXA9, NDUFA4, EFNA3 NSCLC, SCC, ADC [24, 25, 54, 57, 64, 65, 77, 95, 107, 108, 129]
miR-214 Up Dn Dn EZH2, Brn-3b ADC [25, 54, 107]
miR-218 Dn RICTOR ADC [24, 25, 64]
miR-221 Up/UC Dn p27, PTEN, TIMP3 NSCLC [10, 50, 80]
miR-222 Up/UC Dn p27, PTEN, TIMP3 [10, 50, 54]
miR-223 Dn/Up Dn Dn LMO2-L/-S, CEBP-β NSCLC [54, 60, 65]
miR-224 Dn/Up Dn DIO1 [77]
miR-324-5p Up Up Up Up/Dn Smo, Gli1 SCC [10, 54, 65, 130]
miR-326 Up Up MRP-1/ABCC1, Ets-1 [10, 131, 132]
miR-335 Dn Up Up SOD2, Txnrd2, BCLw, SP1, ERα, IGF1R [24, 54, 133–135]
miR-338 Dn Up Up/Dn Runx2, Smo [10, 24, 54, 130, 136]
miR-375 Up Dn Up Up IGF1R, SP1, LDHB, YAP1 ADC SCLC [54, 64, 137–140]
miR-423 Up p21 SCC [24, 65, 141]
miR-429 Dn Up ALDH1L2, PSAT1, ZEB1 SCC [54, 65, 142]
miR-451 Dn Dn RAB14, apoptosis [23, 24, 54]
miR-453 Dn ESR1 SCC [77, 78, 82]
miR-486 Dn CD40 ADC NSCLC [64, 65, 108]
miR-494 Dn Up Nucleolin, Bmal1 SCC [54, 77, 78, 143, 144]
miR-497 Dn Dn BCL2, CCND2 [24, 54, 145]{Xing, 2010 #85
miR-504 Up p53, DRD1 [23, 146, 147]
miR-511 Up Dn TLR4, CD80 SCC [54, 77, 78, 148]
miR-512 Dn c-FLIP, Mcl-1 [54, 149, 150]
1

Expression trend can be either positively or negatively correlated to overall survival

2

Associated with drug response and not to overall survival

Abbreviations: Lines = cell lines, SCC = lung squamous cell carcinoma, ADC = lung adenocarcinoma, Up = increased expression, Dn = decreased expression, UC = no change